论文部分内容阅读
目的:探讨分析低分子肝素钙治疗肺心病合并呼吸衰竭的临床疗效。方法:选取2015年12月至2016年12月在我院接受治疗的80例肺心病合并呼吸衰竭进行研究,所有患者均采取低分子肝素钙治疗,实验结束之后,对治疗前后PaO_2、PaCO_2进行比较分析。结果:治疗前患者PaCO_2明显高于治疗后,PaO_2明显低于治疗后。结论:低分子肝素钙治疗肺心病合并呼吸衰竭的疗效显著,安全性较高,可有效改善患者通气状况以及心肺功能,降低死亡率,值得临床推广应用。
Objective: To investigate the clinical efficacy of low molecular weight heparin in the treatment of pulmonary heart disease complicated with respiratory failure. Methods: Eighty patients with pulmonary heart disease and respiratory failure who were treated in our hospital from December 2015 to December 2016 were selected. All patients were treated with low molecular weight heparin calcium. After the experiment was finished, PaO_2 and PaCO_2 were compared before and after treatment analysis. Results: Before treatment, PaCO 2 was significantly higher than that after treatment, PaO 2 was significantly lower than after treatment. Conclusion: The therapeutic effect of low molecular weight heparin on pulmonary heart disease complicated with respiratory failure is significant and safe. It can effectively improve ventilation and cardiopulmonary function, reduce mortality and is worthy of clinical application.